
Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes
pharmafile | November 7, 2018 | News story | Research and Development | Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes
Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint and “significantly reduced” the occurrence of major cardiovascular events (MACE) in patients with type 2 diabetes mellitus.
In the study, MACE included cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke.
The REWIND trial set itself apart from many similar studies by merit of its small population of participants with establish cardiovascular disease – just 31% – which allowed for a more insightful look into Trulicity’s effects on a broader range of those with type 2 diabetes.
Additionally, the study had the longest median follow-up period of any CV outcomes trial in the GLP-1 receptor agonist class, at more than five years.
“The REWIND study was ambitious, assessing whether dulaglutide could protect a broad range of people with type 2 diabetes, including a high proportion of patients without established cardiovascular disease, from experiencing a cardiovascular event,” explained Dr Arash Tahbaz, Senior Medical Director at Eli Lilly and Company UK and Northern Europe. “The initial study outcomes are compelling and we look forward to analysing and reporting all of the data.”
Matt Fellows
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …






